TipRanks
Neurocrine (IT:1NBIX)
:1NBIX
Italy Market
1NBIX
Neurocrine
RESEARCH TOOLSreports

Neurocrine (1NBIX) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

1NBIX Analyst Ratings

Strong Buy
26Ratings
Strong Buy
23 Buy
3 Hold
0 Sell
Based on 26 analysts giving stock ratings to
Neurocrine
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1NBIX Stock 12 Month Forecast

Average Price Target

€184.92
▲(37.34% Upside)
Based on 26 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is €184.92 with a high forecast of €223.34 and a low forecast of €145.66. The average price target represents a 37.34% change from the last price of €134.65.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"110":"€110","167":"€167","224":"€224","138.5":"€138.5","195.5":"€195.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":223.34335265,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€223.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":184.924764874,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€184.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":145.65870825,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€145.66</span>\n  </div></div>","useHTML":true}}],"tickPositions":[110,138.5,167,195.5,224],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,126.7,134.13410405,141.5682081,149.00231215,156.4364162,163.87052025,171.3046243,178.73872835,186.1728324,193.60693645,201.0410405,208.47514455,215.9092486,{"y":223.34335265,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,126.7,131.17882806723077,135.65765613446155,140.13648420169233,144.61531226892308,149.09414033615386,153.5729684033846,158.0517964706154,162.53062453784617,167.00945260507694,171.4882806723077,175.96710873953847,180.44593680676923,{"y":184.924764874,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,126.7,128.15836217307694,129.61672434615386,131.07508651923078,132.5334486923077,133.99181086538462,135.45017303846154,136.90853521153846,138.36689738461538,139.8252595576923,141.28362173076923,142.74198390384615,144.20034607692307,{"y":145.65870825,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":119.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":132.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.05,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.55,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.35,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.95,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.65,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147.55,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":145.75,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.4,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.7,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€223.34Average Price Target€184.92Lowest Price Target€145.66
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on IT:1NBIX
David Amsellem
Piper Sandler
Piper Sandler
€185.38
Buy
37.68%
Upside
Reiterated
10/01/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tango Therapeutics (NASDAQ: TNGX), Neurocrine (NASDAQ: NBIX) and United Therapeutics (NASDAQ: UTHR)
Jefferies Analyst forecast on IT:1NBIX
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€194.21
Buy
44.23%
Upside
Reiterated
09/29/26
Neurocrine (NBIX) Receives a Buy from Jefferies
UBS Analyst forecast on IT:1NBIX
Ashwani Verma
UBS
UBS
€203.92→€188.91
Buy
40.30%
Upside
Reiterated
09/28/26
Neurocrine price target lowered to $214 from $231 at UBSNeurocrine price target lowered to $214 from $231 at UBS
Bernstein Analyst forecast on IT:1NBIX
Jeffrey Walch
Bernstein
Bernstein
€192.45
Buy
42.92%
Upside
Reiterated
09/25/26
Bernstein Remains a Buy on Neurocrine (NBIX)
RBC Capital Analyst forecast on IT:1NBIX
Brian Abrahams
RBC Capital
RBC Capital
€174.79→€165.08
Buy
22.60%
Upside
Reiterated
09/21/26
Neurocrine (NBIX) Gets a Buy from RBC Capital
CCB Intl. Analyst forecast on IT:1NBIX
Unknown Analyst
CCB Intl.
Not Ranked
CCB Intl.
€165.96
Buy
23.25%
Upside
Initiated
09/18/26
Neurocrine (NBIX) Receives a Buy from CCB Intl.
Morgan Stanley Analyst forecast on IT:1NBIX
Sean Laaman
Morgan Stanley
Morgan Stanley
€160.67→€161.55
Hold
19.98%
Upside
Assigned
09/11/26
Neurocrine price target raised to $183 from $182 at Morgan StanleyNeurocrine price target raised to $183 from $182 at Morgan Stanley
Citi Analyst forecast on IT:1NBIX
Yigal Nochomovitz
Citi
Citi
€219.81→€223.34
Buy
65.87%
Upside
Reiterated
09/04/26
Neurocrine price target raised to $253 from $249 at CitiNeurocrine price target raised to $253 from $249 at Citi
Evercore ISI Analyst forecast on IT:1NBIX
Cory Kasimov
Evercore ISI
Evercore ISI
€185.38→€189.8
Buy
40.96%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: OmniAb (NASDAQ: OABI), Neurocrine (NASDAQ: NBIX) and Evaxion Biotech (NASDAQ: EVAX)
BMO Capital Analyst forecast on IT:1NBIX
Evan Seigerman
BMO Capital
BMO Capital
€167.73
Hold
24.57%
Upside
Reiterated
08/17/26
Neurocrine (NBIX) Gets a Hold from BMO Capital
Deutsche Bank Analyst forecast on IT:1NBIX
David Hoang
Deutsche Bank
Deutsche Bank
€167.73→€145.66
Hold
8.18%
Upside
Assigned
08/13/26
Deutsche Bank Sticks to Its Hold Rating for Neurocrine (NBIX)
J.P. Morgan Analyst forecast on IT:1NBIX
Anupam Rama
J.P. Morgan
J.P. Morgan
€163.31→€191.56
Buy
42.27%
Upside
Reiterated
08/06/26
J.P. Morgan Reaffirms Their Buy Rating on Neurocrine (NBIX)
Wedbush Analyst forecast on IT:1NBIX
Laura Chico
Wedbush
Wedbush
€163.31→€171.26
Buy
27.19%
Upside
Reiterated
08/03/26
Neurocrine price target raised to $194 from $185 at WedbushNeurocrine price target raised to $194 from $185 at Wedbush
Canaccord Genuity Analyst forecast on IT:1NBIX
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
€176.56→€185.38
Buy
37.68%
Upside
Reiterated
08/03/26
Neurocrine (NBIX) Receives a Buy from Canaccord Genuity
Truist Financial Analyst forecast on IT:1NBIX
Danielle Brill
Truist Financial
Truist Financial
€188.03
Buy
39.65%
Upside
Reiterated
08/03/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Neurocrine (NASDAQ: NBIX) and Genmab (NASDAQ: GMAB)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on IT:1NBIX
David Amsellem
Piper Sandler
Piper Sandler
€185.38
Buy
37.68%
Upside
Reiterated
10/01/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tango Therapeutics (NASDAQ: TNGX), Neurocrine (NASDAQ: NBIX) and United Therapeutics (NASDAQ: UTHR)
Jefferies Analyst forecast on IT:1NBIX
Unknown Analyst
Jefferies
Not Ranked
Jefferies
€194.21
Buy
44.23%
Upside
Reiterated
09/29/26
Neurocrine (NBIX) Receives a Buy from Jefferies
UBS Analyst forecast on IT:1NBIX
Ashwani Verma
UBS
UBS
€203.92→€188.91
Buy
40.30%
Upside
Reiterated
09/28/26
Neurocrine price target lowered to $214 from $231 at UBSNeurocrine price target lowered to $214 from $231 at UBS
Bernstein Analyst forecast on IT:1NBIX
Jeffrey Walch
Bernstein
Bernstein
€192.45
Buy
42.92%
Upside
Reiterated
09/25/26
Bernstein Remains a Buy on Neurocrine (NBIX)
RBC Capital Analyst forecast on IT:1NBIX
Brian Abrahams
RBC Capital
RBC Capital
€174.79→€165.08
Buy
22.60%
Upside
Reiterated
09/21/26
Neurocrine (NBIX) Gets a Buy from RBC Capital
CCB Intl. Analyst forecast on IT:1NBIX
Unknown Analyst
CCB Intl.
Not Ranked
CCB Intl.
€165.96
Buy
23.25%
Upside
Initiated
09/18/26
Neurocrine (NBIX) Receives a Buy from CCB Intl.
Morgan Stanley Analyst forecast on IT:1NBIX
Sean Laaman
Morgan Stanley
Morgan Stanley
€160.67→€161.55
Hold
19.98%
Upside
Assigned
09/11/26
Neurocrine price target raised to $183 from $182 at Morgan StanleyNeurocrine price target raised to $183 from $182 at Morgan Stanley
Citi Analyst forecast on IT:1NBIX
Yigal Nochomovitz
Citi
Citi
€219.81→€223.34
Buy
65.87%
Upside
Reiterated
09/04/26
Neurocrine price target raised to $253 from $249 at CitiNeurocrine price target raised to $253 from $249 at Citi
Evercore ISI Analyst forecast on IT:1NBIX
Cory Kasimov
Evercore ISI
Evercore ISI
€185.38→€189.8
Buy
40.96%
Upside
Reiterated
08/17/26
Analysts Offer Insights on Healthcare Companies: OmniAb (NASDAQ: OABI), Neurocrine (NASDAQ: NBIX) and Evaxion Biotech (NASDAQ: EVAX)
BMO Capital Analyst forecast on IT:1NBIX
Evan Seigerman
BMO Capital
BMO Capital
€167.73
Hold
24.57%
Upside
Reiterated
08/17/26
Neurocrine (NBIX) Gets a Hold from BMO Capital
Deutsche Bank Analyst forecast on IT:1NBIX
David Hoang
Deutsche Bank
Deutsche Bank
€167.73→€145.66
Hold
8.18%
Upside
Assigned
08/13/26
Deutsche Bank Sticks to Its Hold Rating for Neurocrine (NBIX)
J.P. Morgan Analyst forecast on IT:1NBIX
Anupam Rama
J.P. Morgan
J.P. Morgan
€163.31→€191.56
Buy
42.27%
Upside
Reiterated
08/06/26
J.P. Morgan Reaffirms Their Buy Rating on Neurocrine (NBIX)
Wedbush Analyst forecast on IT:1NBIX
Laura Chico
Wedbush
Wedbush
€163.31→€171.26
Buy
27.19%
Upside
Reiterated
08/03/26
Neurocrine price target raised to $194 from $185 at WedbushNeurocrine price target raised to $194 from $185 at Wedbush
Canaccord Genuity Analyst forecast on IT:1NBIX
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
€176.56→€185.38
Buy
37.68%
Upside
Reiterated
08/03/26
Neurocrine (NBIX) Receives a Buy from Canaccord Genuity
Truist Financial Analyst forecast on IT:1NBIX
Danielle Brill
Truist Financial
Truist Financial
€188.03
Buy
39.65%
Upside
Reiterated
08/03/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Neurocrine (NASDAQ: NBIX) and Genmab (NASDAQ: GMAB)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ONCBeOne Medicines
OVIDOvid Therapeutics
WSTWest Pharmaceutical Services
ZYMEZymeworks
SLDBSolid Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurocrine

3 Months
Jay OlsonOppenheimer
Success Rate
17/26 ratings generated profit
65%
Average Return
+3.18%
Copying Jay Olson's trades and holding each position for 3 Months would result in 65.38% of your transactions generating a profit, with an average return of +3.18% per trade.
1 Year
Laura ChicoWedbush
Success Rate
16/24 ratings generated profit
67%
Average Return
+4.01%
Copying Laura Chico's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +4.01% per trade.
2 Years
Brian SkorneyRobert W. Baird
Success Rate
21/28 ratings generated profit
75%
Average Return
+16.98%
Copying Brian Skorney's trades and holding each position for 2 Years would result in 75.00% of your transactions generating a profit, with an average return of +16.98% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1NBIX Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
8
4
1
4
4
Buy
30
44
36
35
12
Hold
8
8
9
10
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
46
56
46
49
22
In the current month, 1NBIX has received 16 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. 1NBIX average Analyst price target in the past 3 months is 184.92.
Each month's total comprises the sum of three months' worth of ratings.

1NBIX Financial Forecast

1NBIX Earnings Forecast

Next quarter’s earnings estimate for 1NBIX is €1.71 with a range of €1.18 to €2.12. The previous quarter’s EPS was €1.24. 1NBIX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1NBIX has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1NBIX is €1.71 with a range of €1.18 to €2.12. The previous quarter’s EPS was €1.24. 1NBIX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1NBIX has Performed in-line its overall industry.

1NBIX Sales Forecast

Next quarter’s sales forecast for 1NBIX is €930.11M with a range of €907.59M to €978.22M. The previous quarter’s sales results were €853.31M. 1NBIX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1NBIX has Performed in-line its overall industry.
Next quarter’s sales forecast for 1NBIX is €930.11M with a range of €907.59M to €978.22M. The previous quarter’s sales results were €853.31M. 1NBIX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1NBIX has Performed in-line its overall industry.

1NBIX Stock Forecast FAQ

What is IT:1NBIX’s average 12-month price target, according to analysts?
Based on analyst ratings, Neurocrine’s 12-month average price target is 184.92.
    What is IT:1NBIX’s upside potential, based on the analysts’ average price target?
    Neurocrine has 37.34% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Neurocrine a Buy, Sell or Hold?
          Neurocrine has a consensus rating of Strong Buy, which is based on 23 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Neurocrine’s share price target?
            The average share price target for Neurocrine is 184.92. This is based on 26 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €223.34 ,and the lowest forecast is €145.66. The average share price target represents 37.34% Increase from the current price of €134.65.
              What do analysts say about Neurocrine?
              Neurocrine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 26 Wall Streets Analysts.
                How can I buy shares of Neurocrine?
                To buy shares of IT:1NBIX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.